Pharmaceutical distribution

Last updated

The distribution of medications has special drug safety and security considerations. [1] Some drugs require cold chain management in their distribution. [2]

Contents

The industry uses track and trace technology, though the timings for implementation and the information required vary across different countries, with varying laws and standards.[ citation needed ]

Regulation

Because governments regulate access to drugs, governments control drug distribution and the drug supply chain more than trade for other goods. [3] Distribution begins with the pharmaceutical industry manufacturing drugs. [3] From there, intermediaries in the public sector, private sector, and non-governmental organizations acquire drugs to provide them to other intermediaries. [3] Eventually, the drugs reach different classes of consumers who use them. [3]

Good distribution practice (GDP) is a quality warranty system, which includes requirements for purchase, receiving, storage and export of drugs intended for human consumption. It regulates the division and movement of pharmaceutical products from the premises of the manufacturer of medicinal products, or another central point, to the end user thereof, or to an intermediate point by means of various transport methods, via various storage and/or health establishments.

Argentina

In 2011, Argentina introduced a catalogue of drugs covered by its national drug traceability scheme, listing more than 3,000 drugs that require the placing of unique serial numbers and tamper-evident features on the secondary packaging.[ citation needed ] The drugs listed are recorded in real time in a central database managed by the National Administration of Drugs, Foods, Medical Devices of Argentina (ANMAT), Regulation 3683, which uses Global Location Numbers (GLNs) to identify the various actors in the supply chain. The purpose of this program is to actively limit the use of illegal drugs. [4]

Brazil

The 2009 Brazilian Federal Law 11.903 and subsequent regulations of the National Agency for Sanitary Surveillance in Brazil (ANVISA) require that a 2D data matrix code be put on all secondary packaging. Under these provisions, manufacturers will be required to maintain a database of all transactions from manufacturing to dispensing, while distributors must report serialized transaction data to the manufacturer and keep a database of suppliers, medicine recipients, and packing companies. [5]

Data Element – National Number, Expiration Date, Batch/Lot Number, Serial Number [6]

China

In 2008, China’s State Food and Drug Administration (CFDA) made serialization mandatory for over 275 therapeutic classes of individual saleable product units by December 2015. The CFDA does not follow an international standard. Manufacturers may only register their products and obtain their serial numbers by applying to the China Product Identification, Authentication and Tracking System (PIATS). They must also implement a quality control system with an electronic drug-monitoring system, a standardized documentation system, and bar codes to ensure pharmaceutical traceability. Companies importing drugs into China must designate a local pharmaceutical company or wholesaler as their electronic monitoring agent in the country. In addition to legislative reforms, China has increased enforcement efforts at the provincial and local levels. In 2013, the Chinese government coordinated joint special enforcement campaigns targeting counterfeit drugs. [7] China regulations are currently on hold.

Europe

In Europe GDP is based on the Commission Directive (EU) 2017/1572 of 15 September 2017 supplementing Directive 2001/83/EC of the European Parliament and of the Council as regards the principles and guidelines of good manufacturing practice for medicinal products for human use.

In 2016, the European Medicines Agency adopted the Falsified Medicines Directive (FMD), which requires all pharmaceutical products sold in the EU to feature obligatory “safety features.” This directive is scheduled to launch in the first quarter of 2019. By February 9, 2019, all pharmaceutical companies will be required to connect their internal systems to the EU data repository, which contains the product master data and batch information. This will allow pharmacists and consumers to authenticate their medicines.[ citation needed ]

United States

In the US, Good Manufacturing Practice (GMP) Regulations are based on the Code of Federal Regulations 21 CFR 210/211, and USP 1079.

The US Drug Supply and Chain Security Act (DSCSA), was enacted by Congress on November 26, 2013 and outlines requirements to build electronic systems that identify and trace prescription drugs distributed in the US. [8] By November 27th 2023, full electronic track & trace capability will be required for all partners in the supply chain. [9]

Illegal drugs

An illegal drug trade operates to distribute illegal drugs. The trade of illegal drugs overlaps with trade in contraband of all sorts. [10] [11] Illegal drug distribution does not overlap in obvious ways with the legal trade of legal drugs. [12]

See also

Related Research Articles

<span class="mw-page-title-main">Good manufacturing practice</span> Manufacturing quality standards

Current good manufacturing practices (cGMP) are those conforming to the guidelines recommended by relevant agencies. Those agencies control the authorization and licensing of the manufacture and sale of food and beverages, cosmetics, pharmaceutical products, dietary supplements, and medical devices. These guidelines provide minimum requirements that a manufacturer must meet to assure that their products are consistently high in quality, from batch to batch, for their intended use.

GxP is a general abbreviation for the "good practice" quality guidelines and regulations. The "x" stands for the various fields, including the pharmaceutical and food industries, for example good agricultural practice, or GAP.

<span class="mw-page-title-main">Regulation of therapeutic goods</span> Legal management of drugs and restricted substances

The regulation of therapeutic goods, defined as drugs and therapeutic devices, varies by jurisdiction. In some countries, such as the United States, they are regulated at the national level by a single agency. In other jurisdictions they are regulated at the state level, or at both state and national levels by various bodies, as in Australia.

Canada Drugs otherwise known as CanadaDrugs.com, was an online pharmacy based in Winnipeg, Manitoba.

Good clinical practice (GCP) is an international quality standard, which governments can then transpose into regulations for clinical trials involving human subjects. GCP follows the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), and enforces tight guidelines on ethical aspects of clinical research.

<span class="mw-page-title-main">Cold chain</span> Low-temperature supply chain

Cold chain is a set of rules and procedures that ensure the systematic coordination of activities for ensuring temperature-control of goods while in storage and transit. The objective of a cold chain is to preserve the integrity and quality of goods such as pharmaceutical products or perishable good from production to consumption. Cold chain management earned its name as a "chain" because it involves linking a set of storage locations and special transport equipment, required for ensuring that temperature conditions for goods are met, while they are in storage or in transit from production to consumption, akin to the interconnected links of a physical chain.

The pharmaceutical industry is one of the leading industries in the People's Republic of China, covering synthetic chemicals and drugs, prepared Chinese medicines, medical devices, apparatus and instruments, hygiene materials, packing materials, and pharmaceutical machinery. China has the second-largest pharmaceutical market in the world as of 2017 which is worth US$110 billion. China accounts for 20% of the world's population but only a small fraction of the global drug market. China's changing health-care environment is designed to extend basic health insurance to a larger portion of the population and give individuals greater access to products and services. Following the period of change, the pharmaceutical industry is expected to continue its expansion.

The Principles of Good Laboratory Practice (GLP) establish rules and criteria for a quality system that oversees the organizational processes and conditions in which non-clinical health and environmental safety studies are planned, conducted, monitored, recorded, reported, and archived. These principles apply to the non-clinical safety testing of substances found in various products to ensure the quality and integrity of the safety data submitted to regulatory authorities globally.

In the distribution and logistics of many types of products, track and trace or tracking and tracing concerns a process of determining the current and past locations of a unique item or property. Mass serialization is the process that manufacturers go through to assign and mark each of their products with a unique identifier such as an Electronic Product Code (EPC) for track and trace purposes. The marking or "tagging" of products is usually completed within the manufacturing process through the use of various combinations of human readable or machine readable technologies such as DataMatrix barcodes or RFID.

The process of establishing documentary evidence demonstrating that a procedure, process, or activity carried out in testing and then production maintains the desired level of compliance at all stages. In the pharmaceutical industry, it is very important that in addition to final testing and compliance of products, it is also assured that the process will consistently produce the expected results. The desired results are established in terms of specifications for outcome of the process. Qualification of systems and equipment is therefore a part of the process of validation. Validation is a requirement of food, drug and pharmaceutical regulating agencies such as the US FDA and their good manufacturing practices guidelines. Since a wide variety of procedures, processes, and activities need to be validated, the field of validation is divided into a number of subsections including the following:

An online pharmacy, internet pharmacy, or mail-order pharmacy is a pharmacy that operates over the Internet and sends orders to customers through mail, shipping companies, or online pharmacy web portal.

<span class="mw-page-title-main">EudraLex</span> EU laws on medicinal products

EudraLex is the collection of rules and regulations governing medicinal products in the European Union.

<span class="mw-page-title-main">European Directorate for the Quality of Medicines & HealthCare</span> International organisation

The European Directorate for the Quality of Medicines & HealthCare (EDQM) is a Directorate and partial agreement of the Council of Europe that traces its origins and statutes to the Convention on the Elaboration of a European Pharmacopoeia.

<span class="mw-page-title-main">Epedigree</span> Electronic document which provides data on the history of a particular batch of a drug

An epedigree is an electronic document which provides data on the history of a particular batch of a drug. It satisfies the requirement for a drug pedigree while using a convenient electronic form.

A counterfeit medication or a counterfeit drug is a medication or pharmaceutical item which is produced and sold with the intent to deceptively represent its origin, authenticity, or effectiveness. A counterfeit drug may contain inappropriate quantities of active ingredients, or none, may be improperly processed within the body, may contain ingredients that are not on the label, or may be supplied with inaccurate or fake packaging and labeling. Counterfeit drugs are related to pharma fraud. Drug manufacturers and distributors are increasingly investing in countermeasures, such as traceability and authentication technologies, to try to minimise the impact of counterfeit drugs. Antibiotics with insufficient quantities of an active ingredient add to the problem of antibiotic resistance.

Produce traceability makes it possible to track produce from its point of origin to a retail location where it is purchased by consumers.

<span class="mw-page-title-main">Drug packaging</span> Packaging for pharmaceutical preparations

Drug packaging is process of packing pharmaceutical preparations for distribution, and the physical packaging in which they are stored. It involves all of the operations from production through drug distribution channels to the end consumer.

Pharmaceutical fraud is when pharmaceutical companies engage in illegal, fraudulent activities to the detriment of patients and/or insurers. Examples include counterfeit drugs that do not contain the active ingredient, false claims in packaging and marketing, suppression of negative information regarding the efficacy or safety of the drug, and violating pricing regulations.

The online distribution of counterfeit medicines has been growing during the last decades. The role of Internet as an unregulated medicine market is the main reasons behind this phenomenon, especially the effectiveness of "spam" as a tool for advertising and promoting these products. Websites and social media are new powerful instruments that organized criminal groups could exploit to conduct their illicit businesses. The spread of this emerging threat worldwide poses a very high risk for the health and safety of unaware consumers.

<span class="mw-page-title-main">Drug Quality and Security Act</span>

The Drug Quality and Security Act is a law that amended the Federal Food, Drug, and Cosmetic Act to grant the Food and Drug Administration more authority to regulate and monitor the manufacturing of compounded drugs. The bill was written in response to the New England Compounding Center meningitis outbreak that took place in 2012, which killed 64 people. The bill was signed by President Obama on November 27, 2013.

References

  1. Marucheck, Ann; Greis, Noel; Mena, Carlos; Cai, Linning (November 2011). "Product safety and security in the global supply chain: Issues, challenges and research opportunities". Journal of Operations Management. 29 (7–8): 707–720. doi:10.1016/j.jom.2011.06.007.
  2. Bishara, Rafik H. (January 2006). "Cold Chain Management - An Essential Component of the Global Pharmaceutical Supply Chain" (PDF). American Pharmaceutical Review.
  3. 1 2 3 4 Committee on Understanding the Global Public Health Implications of Substandard, Falsified, and Counterfeit Medical Products; Board on Global Health; National Academy of Medicine (2013). "Weaknesses in the Drug Distribution Chain". In Buckley, Gillian J.; Gostin, Lawrence O. (eds.). Countering the problem of falsified and substandard drugs (Édition abrégée du rapport : "Parer au problème des médicaments falsifiés ou de qualité inférieure" publié en 2013. ed.). Washington, D.C.: National Academies Press. ISBN   978-0-309-26939-1.{{cite book}}: CS1 maint: multiple names: authors list (link)
  4. Successful cases of Traceability in the Healthcare Sector in Argentina (PDF). Association of Private Clinics, Sanatoriums and Hospitals of the Argentine Republic. January 2014. Retrieved 4 October 2016.
  5. Pharmaceutical Serialization Track & Trace: Easy Guide to Country-Wise Mandates. Infosy Limited. 2014.
  6. reserved, Mettler-Toledo International Inc. all rights. "Serialization Whitepaper". www.mt.com (in German). Retrieved 2017-12-18.
  7. Buthusiem, Edward J. "Drug Serialization Trends and Developments". Pharmaceutical Compliance Monitor. Retrieved 4 October 2016.
  8. Research, Center for Drug Evaluation and. "Drug Supply Chain Security Act (DSCSA)". www.fda.gov. Retrieved 2018-03-13.
  9. Research, Center for Drug Evaluation and (2019-02-09). "Drug Supply Chain Security Act (DSCSA) Implementation Plan". FDA.
  10. Bruinsma, Gerben; Bernasco, Wim (February 2004). "Criminal groups and transnational illegal markets". Crime, Law and Social Change. 41 (1): 79–94. doi:10.1023/B:CRIS.0000015283.13923.aa. S2CID   35115663.
  11. HALLER, MARK H. (May 1990). "Illegal Enterprise: A Theoretical and Historical Interpretation". Criminology. 28 (2): 207–236. doi:10.1111/j.1745-9125.1990.tb01324.x.
  12. Passas, Nikos (1 January 2003). "Cross-border Crime and the Interface between Legal and Illegal Actors". Security Journal. 16 (1): 19–37. doi:10.1057/palgrave.sj.8340123. S2CID   154651843.